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Abstract  
Background: COVID-19 disease has spread globally and was declared a pandemic on March 11, 
2020 by the World Health Organization. On March 10th, the State of Michigan confirmed its first 
two cases of COVID-19 and since then the number of confirmed cases has reached 47,182 as of 
May 11, 2020 with 4,555 deaths. 
Setting: Currently, little is known if patients living with HIV (PLWH) are at higher risk of 
severe COVID-19 or if their antiretrovirals are protective. This study presents epidemiologic and 
clinical features of COVID-19 infected PLWH in Detroit, Michigan. 
Methods: This is a case series that included 14 PLWH with laboratory-confirmed COVID-19 
infection who were evaluated at Henry Ford Hospital (HFH) in Detroit, Michigan between 
March 20 and April 30, 2020. 
Results: 14 PLWH were diagnosed with COVID-19. Twelve patients were male and two were 
female; 13 of the 14 patients were virally suppressed. Eight patients were hospitalized, and six 
patients were told to self-quarantine at home following their diagnoses. Three patients who were 
admitted expired during their hospital stay. No patient required bilevel positive airway pressure 
or nebulizer use in the emergency department and none developed acute respiratory distress 
syndrome, pulmonary embolism, deep venous thrombosis, or a cytokine storm while on therapy 
for COVID-19.  
Conclusion: Although the clinical spectrum of COVID-19 among PLWH cannot be fully 
ascertained by this report, it adds to the data that suggests that HIV-positive patients with SARS-
CoV-2 infection are not at a greater risk of severe disease or death as compared to HIV-negative 
patients. 
Keywords: HIV, COVID-19, SARS-CoV-2, cART, tenofovir  
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Introduction 
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus first 
detected in December 2019 in Wuhan, Hubei Province, China 1. Many of the initial cases had a 
common exposure to the Huanan wholesale seafood market that also traded live animals 2. 
SARS-CoV-2 was then identified on January 7, 2020 by the Chinese Center for Disease Control 
and Prevention, which then disclosed the genomic sequence on January 11, 2020 3. The World 
Health Organization named the infection caused by SARS-CoV-2, COVID-19. Since the initial 
detection of COVID-19, the disease has spread globally and was declared a pandemic on March 
11, 2020 by the World Health Organization 4. In the United States, Detroit, Michigan had 
become a ”hotspot” of COVID-19 infected patients with the number of confirmed cases reaching 
47,182 as of May 8, 2020 with 4,555 deaths in Michigan (fourth most deaths in the U.S.) 5.  
Currently, little is known if people living with HIV (PLWH) are at higher risk of severe COVID-
19 or if antiretroviral medications used to treat HIV are protective against severe COVID-19. 
Tenofovir has been shown in vitro to tightly bind to the SARS-CoV-2 RNA-dependent RNA 
polymerase 6. Alternatively, lopinavir-ritonavir has already been shown to have no benefit 
beyond standard care in a large randomized control trial 7,8. Additionally, little is known if and 
how frequently PLWH mount the intense cytokine response leading to cytokine storm and severe 
COVID-19. We describe our single-center experience in Detroit, Michigan of COVID-19 in 
patients infected with HIV-1. We reviewed patients’ demographics, clinical characteristics of 
both their HIV and COVID-19 co-infections, the antiviral and antiretroviral treatments they 
received, and their clinical outcomes.  
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Methods 
This is a case series that included 14 PLWH who were evaluated in the Henry Ford Hospital 
(HFH) emergency department for laboratory-confirmed COVID-19 infection, between March 20 
and April 30, 2020. A confirmed case of COVID-19 was defined by a positive result on a reverse 
transcriptase-polymerase chain reaction assay of a nasopharyngeal swab sample. Patients were 
identified and clinical data were collected from electronic medical records. All laboratory tests 
and radiological assessments were performed at the discretion of the treating physician.  
Categorical variables were analyzed using the chi-square test. Approval from the Henry Ford 
Health System Institutional Review Board was obtained. 
 
Results 
From March 20, 2020 to April 30, 2020, 7,372 people tested positive for COVID-19 at HFH. Of 
this group, 14 were PLWH. Twelve patients were male and two were female. Twelve were 
African American and 2 were Hispanic. Six patients were discharged from the emergency 
department to self-quarantine. Eight patients were admitted to the general practice unit, one of 
whom required supplemental oxygenation. Two of the 8 patients were admitted to the intensive 
care unit and required invasive mechanical ventilation. The average duration of symptoms prior 
to admission was 12 days. The most common presenting complaints were fever (N = 7; 50%), 
shortness of breath (N = 7; 50%), cough (N = 10; 70%), diarrhea (N = 4; 29%), and loss of taste 
and smell (N = 4; 29%). One patient endorsed prior travel to Texas and two patients endorsed 
exposure as healthcare workers. Baseline characteristics of the patients are shown in Table 1. 
The most common comorbidities included obesity (N = 8; 57%), hypertension (N = 8; 57%), 
diabetes (N = 6; 43%), chronic kidney disease (N = 5; 36%) and end-stage renal disease 
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requiring hemodialysis (N = 2; 14%). Past or present smoking and alcohol use was noted in the 
medical histories of seven patients. One patient was previously on an angiotensin-converting 
enzyme inhibitor, 2 patients were on an angiotensin II receptor blocker, and 4 patients were on 
inhaled steroids for either chronic obstructive pulmonary disease or asthma. 
Thirteen patients had suppressed HIV viral loads (Table 1) on combination antiretroviral therapy 
(cART) regimens. One patient was not on cART at presentation. All patients but one on cART 
had a regimen with a tenofovir component, and only 1 patient was on a protease inhibitor-based 
regimen with cobicistat-boosted darunavir. Two patients had a history of an AIDS defining 
illness in the past.  
In the emergency department, antibiotics for community-acquired pneumonia were initiated for 4 
of the 14 patients, intravenous fluids were given to 3 patients, and systemic corticosteroids were 
given to 3 patients. No patient required bilevel positive airway pressure or nebulizer use in the 
emergency department, and none developed acute respiratory distress syndrome, pulmonary 
embolism, deep venous thrombosis, or a cytokine storm while on therapy for COVID-19. Two 
patients were transferred to the intensive care unit during their admission; both expired: one from 
respiratory failure secondary to multifocal pneumonia, and the second one from cardiac arrest 
and had an extensive history of congestive heart failure. The third patient died while on the 
general practice unit from cardiac arrest. Five patients were discharged home. All admitted 
patients received hydroxychloroquine 400 mg PO twice a day for 2 doses followed by 200 mg 
PO twice a day for 4 days. The administration of hydroxychloroquine was consistent with our 
institution’s treatment guidelines during that time period. At 30 days following their COVID-19 
diagnoses, 11 of the 14 PLWH were still alive.  
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Because of cardiac-associated mortality concern in the 3 patients who expired, a further medical 
record review was undertaken with a focus on COVID-19 and hydroxychloroquine associated 
causes. Patient 13 died from worsening heart failure that was severe prior to a COVID-19 
diagnosis. The patient expired in the intensive care unit from pulseless electrical activity arrest 
with no documentation of torsades de pointes noted on cardiac monitoring. Patient 9 expired on 
the general practice unit from a cardiac arrest. He was found pulseless and unresponsive by a 
nurse. This patient had multiple co-morbidities including metastatic cancer, heart failure, lung 
disease requiring oxygenation and end stage renal disease. It is unclear if COVID-19 contributed 
to his cardiac arrest. Patient 1 expired from multifocal pneumonia 14 days from a COVID-19 
confirmed diagnosis; this death was potentially attributable to late complications from COVID-
19 (Table 1).  
 
Discussion 
Although the clinical spectrum of COVID-19 among PLWH cannot be ascertained by this report, 
the course of infection among those described in this report is similar to what has been described 
in the literature 1. A case series from Germany presented 33 virally suppressed PLWH infected 
with COVID-19 with 76% having mild infection, 27% patients having severe infection, and 3% 
patients expiring 9. These findings were also consistent with our results. An observational 
prospective study from Madrid, Spain analyzed 51 PLWH diagnosed with COVID-19 of whom 
69% required hospitalization, 63% had one co-morbidity and 12% were critically ill. The authors 
of this study noted that PLWH should not be considered to be protected from COVID-19 or to 
have a lower risk of severe disease. Therefore, they should receive the same treatment approach 
applied to the general public 10. PLWH at HFH had similar comorbidities and hospital 
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admissions compared to non-HIV patients admitted with COVID-19.  In a recent publication of 
463 patients infected with COVID-19, but without known HIV, the investigators from HFH 
found that the three most common comorbidities were hypertension (63.7%), obesity (57.6%) 
and diabetes (38.4%). Patients in the HFH study also had a 16% overall 30-day mortality rate 11. 
These comorbidities were also the three most common in our population (57%, 57% and 43% 
respectively) with a 21% overall 30-day mortality rate. Our case series, the current published 
literature on HIV and SARS-CoV-2, and the published data from HFH on COVID-19 patients 
without known HIV supports the theory that there is not an excess morbidity and mortality 
among PLWH affected by COVID-19 compared to the general public. 
There are many hypotheses as to why PLWH might have favorable outcomes to COVID-19. One 
hypothesis is that the majority of these patients are on tenofovir-based regimens. Tenofovir has 
been described as having the capacity to bind to SARS-CoV-2 RNA-dependent RNA polymerase 
6
. This mechanism of action is similar to the antiviral drug remdesivir, which has been approved 
for treatment for COVID-19 through emergency use by the FDA. However, the affinity for the 
binding substrate was lowest in tenofovir, compared to galidesivir, remdesivir, and ribavirin 6. 
Tenofovir-emtricitiabine was also recently shown to reduce virus titers in a highly susceptible 
ferret infection model 12. In a Spanish study, PLWH receiving emtricitabine and tenofovir 
disoproxil fumarate were found to have a lower risk for COVID-19 and related hospitalization 
than those receiving other nucleoside reverse transcriptase inhibitors 13. Whether the tenofovir-
based regimen resulted in a reduction in the severity of response to COVID-19 will need to be 
studied further, but this regimen did not protect our patients from acquiring the infection.  
Early cART can blunt the cytokine response in acute HIV infection 14. In addition, tenofovir has 
been shown to have anti-inflammatory effects in cells and tissue from HIV-uninfected donors 
AC
CE
PT
ED
 Copyright © 20 The Author(s). Published by Wolters Kluwer Health, Inc. 20
8 
15,16
. The impact on COVID-19 of ART, early therapy for SARS-CoV-2, or pre-existing 
immunodeficiency is unknown. However, none of these patients developed a clinical syndrome 
compatible with a cytokine storm. While it is of interest that CD4 and CD8 counts fall with 
SARS-CoV-2 infection, it is unknown whether this change exacerbates or dampens the cytokine 
response associated with COVID-19 or leads to an increased risk of secondary infections. 
The absence of reports of COVID-19 among immunosuppressed hosts is striking. The 
susceptibility, disease course, and outcome among PLWH have not been described. Given the 
role of the “cytokine storm” in the outcome of COVID-19 infection, some immunodeficient 
states may be protective in terms of reducing the severity of infection. However, Guan et al. in a 
review of 1,590 patients found that any malignancy was associated with poor clinical outcomes 
regardless of an individual’s HIV status 17. The COVID-19 outbreak in Detroit is at a plateau as 
of May 10, 2020, but the total number of PLWH who have been diagnosed with COVID-19 is 
unknown as universal testing is not consistently performed 18.  The Michigan Department of 
Health and Human Services reported that as of 6/30/2020, 278 of the 17,093 (1.6%) known 
PLWH in Michigan tested positive for COVID-19 with 8% expiring, 21% requiring 
hospitalization and 5% requiring ventilation (Table 2) 19. This is similar to the 1.7% prevalence 
of confirmed COVID-19 in Detroit 5. Of the approximately 1500 PLWH followed in our HIV 
clinic in Detroit, MI, 14 HIV-positive individuals were diagnosed with COVID-19 in our 
laboratories. Others have self-reported to have been diagnosed elsewhere, but due to a lack of 
clinical information these individuals have not been included in this series..  
Our study had some limitations. We had a small sample size, and it is unclear if our findings can 
be applied to a larger number of patients. All patients also received hydroxychloroquine which 
was consistent with our institution’s guidelines during that time period prior to the Emergency 
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Use Authorization being rescinded. However, data remains limited on co-infection with HIV and 
COVID-19, and it is important to share experiences between health care professionals in order to 
enhance our knowledge about COVID-19.  
In conclusion, even though in our series all patients co-infected with HIV and SARS-CoV-2 
were either African American or Hispanic, they experienced a clinical course that was similar to 
that reported in the literature for individuals not infected with HIV. In this small group of 
individuals, we did not observe an unexpected increase in disease severity or mortality. It is 
possible that PLWH are more likely to take precautions to prevent exposure, more likely to seek 
medical care, or more likely to be tested for COVID-19, which may skew data to earlier and less 
symptomatic infection. Nevertheless, we have seen no signals yet to suggest that care for patients 
co-infected with HIV and SARS-CoV-2 should be different from care for patients with COVID-
19 who are not infected with HIV. 
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Table 1. Characteristics Among our Co-infected COVID 19 and HIV Patients at Presentation 
Patient Age 
(years) 
Gender Race/ Ethnicity CD4 cells/mm3 BMI 
(kg/m2) 
HIV-1 Viral Load 
(copies/mL) 
CRP 
(mg/dL) 
ALC 
(K/uL) 
Co-Morbidities  Disposition 
From ED 
1 74 Male Black 523 28.8 <20 21.5 0.2 HTN, DM, CKD GPU to ICU* 
2 57 Male Black 982 55.82 <20 2.1 2.1 COPD, HTN, DM, 
CHF 
GPU 
3 65 Female Black 21 33.32 1646 5.1 1 DM GPU 
4 58 Female Black 482 33.45 <20 N/A N/A DM, CKD Home 
5 39 Male Black 1291 28.7 <20 N/A N/A None Home 
6 64 Male Black 523 34 <20 11.3 0.3 HTN GPU 
7 48 Male Hispanic 516 36.26 <20 11.4 1.5 None GPU 
8 54 Male Hispanic 280 32.92 <20 N/A 0.4 HTN, DM, CKD Home 
9 63 Male Black 242 20.71 26 20.7 0.3 COPD on 2L O2, 
HTN, CHF, ESRD on 
HD 
GPU* 
10 45 Male Black 1756 25.73 <20 N/A N/A None Home 
11 56 Male Black 806 31.2 <20 14.4 0.8 CKD, DM, HTN GPU 
12 36 Male Black 463 23.9 <20 N/A N/A None Home 
13 64 Male Black 145 31.2 35 11.9 1.1 HTN, ESRD on HD, 
COPD, CHF 
GPU to ICU* 
14 64 Male Black 540 23 <20 N/A N/A HTN Home 
ALC, absolute lymphocyte count; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CHF, congestive heart 
failure; CKD, chronic kidney disease; CRP, C-reactive protein; DM, diabetes mellitus; ED, emergency department; ESRD on HD, end 
stage renal disease on hemodialysis; GPU, general practice unit; HTN, hypertension; ICU, intensive care unit; N/A, not available. *, 
Patient expired 
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 Table 2. Summary of Total Number of COVID-19 Cases in Michigan With and Without HIV  
 
Characteristic COVID-19 Patients PLWH Co-Infection with COVID-19 and HIV 
Total Cases 65,271 17,093 278 
Gender 
    Males 
    Females 
 
47% 
53% 
 
79% 
21% 
 
81% 
19% 
Age  
    Mean 
    Median 
 
52 
52 
 
46 
48 
 
49 
51 
Race/Ethnicities 
    Hispanic 
    Black 
    White 
    Unknown 
 
7% 
32% 
39% 
23% 
 
6% 
56% 
34% 
4% 
 
9% 
68% 
16% 
7% 
Deaths (N, %) 5942 (9%) --- 23 (8%) 
Hospitalization (%) 20% --- 21% 
Requiring Ventilation  (%) 3% --- 5% 
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